Semaglutide, an injection medication initially used for regulating blood sugar levels in Type 2 diabetes patients, is being hailed around the world as a weight loss “wonder drug” – just ask Elon Musk, who credits the blockbuster drug for his recent weight loss.
Known under the brand names Ozempic, Wegovy and Mounjaro, semaglutide has generated excitement in the pharmaceutica and medical industries, all but promising a new frontier in tackling obesity. Data from Novo Nordisk, the manufacturers of Ozempic, suggests that US healthcare providers were writing around 60,000 new weekly prescriptions for the drug as of April 2023.
Its rising popularity began after the FDA approved Wegovy, a higher-dose version of Ozempic, as a treatment for chronic obesity in June 2021. Since then, whispers are rife on the red carpets…